Agree... and the market's reaction is favorable. In early stage companies- and especially with the constraints of US drug policy- share dilution is really the only coin of the realm. This appears to be the making of a quite good partnership and looks to be accretive in the long run, as I fully expect Ianthus to do quite well for its shareholders.
News 
Market Data 
Discover 
